RESUMEN
BACKGROUND AND OBJECTIVES: Utilisation of the one-step nucleic acid amplification (OSNA) molecular biology method for the detection of the metastatic involvement of sentinel lymph nodes (SLNs) in endometrial cancer (EC) patients. A comparison with histopathological ultrastaging and a description of the clinical consequences. METHODS: Surgically treated EC patients underwent detection of SLNs. Nodes greater than 5 mm were cut into sections 2-mm thick parallel to the short axis of the node. Odd sections were examined according to the OSNA method, while even ones according to an appropriate ultrastaging protocol. Nodes less than or equal to 5 mm were cut into halves along the longitudinal axis with one half examined according to the OSNA method and the other half by ultrastaging. RESULTS: Fifty-eight patients were included and 135 SLNs were acquired. Both ultrastaging and OSNA agreed on 116 results. According to the OSNA method, 20.69% more patients were classified into International Federation of Gynecology and Obstetrics (FIGO) stage III. When comparing the results of the OSNA method to the conclusions of ultrastaging as a reference method, sensitivity of 90.9%, specificity of 85.5% and concordance of 85.9% were attained. CONCLUSIONS: The results of the OSNA method showed a higher frequency of detection of micrometastases and included 20.69% more patients into FIGO stage III.
Asunto(s)
Adenocarcinoma de Células Claras/secundario , Cistadenocarcinoma Seroso/secundario , Neoplasias Endometriales/patología , Técnicas de Amplificación de Ácido Nucleico/métodos , Ácidos Nucleicos/análisis , Ganglio Linfático Centinela/patología , Adenocarcinoma de Células Claras/genética , Adenocarcinoma de Células Claras/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/genética , Cistadenocarcinoma Seroso/genética , Cistadenocarcinoma Seroso/cirugía , Neoplasias Endometriales/genética , Neoplasias Endometriales/cirugía , Femenino , Estudios de Seguimiento , Humanos , Periodo Intraoperatorio , Queratina-19/genética , Metástasis Linfática , Persona de Mediana Edad , Micrometástasis de Neoplasia , Ácidos Nucleicos/genética , Pronóstico , Ganglio Linfático Centinela/cirugía , Biopsia del Ganglio Linfático Centinela , Tasa de SupervivenciaRESUMEN
BACKGROUND: Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2. METHODS: Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were scheduled for first-line platinum-based CT were eligible. Patients, stratified by tumor residuum (0 or <1 cm), were randomized (1:1:1) to DCVAC/OvCa parallel to CT (Group A), DCVAC/OvCa sequential to CT (Group B), or CT alone (Group C) in Part 1, and to Groups B and C in Part 2. Autologous dendritic cells for DCVAC were differentiated from patients' CD14+ monocytes, pulsed with two allogenic OvCa cell lines (SK-OV-3, OV-90), and matured in the presence of polyinosinic:polycytidylic acid. We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) analysis set in Part 1. RESULTS: Between November 2013 and March 2016, 99 patients were randomized. The mITT (Part 1) comprised 31, 29, and 30 patients in Groups A, B, and C, respectively. Baseline characteristics and DCVAC/OvCa exposure were comparable across the treatment arms. DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5.9%) in Group A and 2 of 53 patients (3.8%) in Group B. Median PFS was 20.3, not reached, and 21.4 months in Groups A, B, and C, respectively. The HR (95% CI) for Group A versus Group C was 0.98 (0.48 to 2.00; p=0.9483) and the HR for Group B versus Group C was 0.39 (0.16 to 0.96; p=0.0336). This was accompanied by a non-significant trend of improved OS in Groups A and B. Median OS was not reached in any group after a median follow-up of 66 months (34% of events). CONCLUSIONS: DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC. TRIAL REGISTRATION NUMBER: NCT02107937, EudraCT2010-021462-30.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carboplatino/uso terapéutico , Carcinoma Epitelial de Ovario/tratamiento farmacológico , Células Dendríticas/inmunología , Inmunoterapia/métodos , Paclitaxel/uso terapéutico , Acetilcisteína/análogos & derivados , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Carboplatino/farmacología , Femenino , Humanos , Ratones , Persona de Mediana Edad , Paclitaxel/farmacología , Adulto JovenRESUMEN
BACKGROUND/AIM: To compare the diagnostic reliability, accuracy and safety of ultrasound-guided biopsy (Tru-Cut biopsy) and ascites puncture in patients with a primarily inoperable malignant ovarian tumor. PATIENTS AND METHODS: This is a retrospective analysis of the studied methods in consecutively examined patients and a prospective validation of these methods. 79 women with a suspected primarily inoperable ovarian tumor underwent Tru-Cut biopsies and were included in the ultrasound-guided biopsy group. In addition, 55 patients after ascites puncture were enrolled in the comparison group. Both procedures were performed in 48 patients for the prospective validation. RESULTS: Significant differences in favour of ultrasound-guided biopsy were found in all studied variables (malignancy confirmation 72.9% vs. 95.8%, tumor origin 52.1% vs. 89.6%, histologic subtype 43.8% vs. 85.4% and accuracy, i.e. agreement of preoperative and definitive diagnosis 43.7% vs. 95.4%). CONCLUSION: Ultrasound-guided biopsy is an accurate, reliable, safe and minimally invasive method. Owing to the high reliability and accuracy, it has the capacity to replace ascites puncture with cytologic examination or a more invasive method (laparoscopy, laparotomy) for adequate tumor sampling.
Asunto(s)
Biopsia Guiada por Imagen , Neoplasias Ováricas/diagnóstico , Punciones , Ultrasonografía , Ascitis/patología , Citodiagnóstico , Femenino , Histocitoquímica , Humanos , Biopsia Guiada por Imagen/métodos , Biopsia Guiada por Imagen/normas , Punciones/métodos , Reproducibilidad de los Resultados , Estudios Retrospectivos , Ultrasonografía/métodosRESUMEN
BACKGROUND: An ovarian cancer marker panel including leptin, prolactin, osteopontin, insulin-like growth factor II (IGFII), macrophage migration inhibitory factor and CA125 was tested for multiplex marker measurement. Multiplex was compared to single assayed tumour markers: CA125, TPS, thymidine kinase, monototal and HE4. PATIENTS AND METHODS: The serum marker levels in ovarian cancer patients were compared to controls with benign ovarian disease. xMAP technology was used for multiplex panel and routine immunoanalytic methods for other markers. RESULTS: Considering the multiplexed markers, only CA125(Luminex), osteopontin and IGF-II differed significantly between groups. Levels of all non-multiplexed tumour markers were significantly higher in the cancer group compare to the control. CONCLUSION: Multiplex is a powerful tool for multiparametric studies, but we are still in the era of looking for the right marker combinations for cancer diagnostics and monitoring. The panel will be tested on a larger ovarian cancer cohort and in patients with other cancer and non-cancerous diseases.
Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias Ováricas/sangre , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antígeno Ca-125/sangre , Proteínas Secretorias del Epidídimo/metabolismo , Femenino , Humanos , Persona de Mediana Edad , Péptidos/sangre , Análisis por Matrices de Proteínas/métodos , Timidina Quinasa/sangre , Adulto Joven , beta-DefensinasRESUMEN
AIM: To analyze the utility of HE4 assessment in preoperative management of patients with early-stage endometrial cancer for stratification into low-risk and high-risk groups. PATIENTS AND METHODS: The following data were prospectively collected from patients operated for endometrial cancer from 05/2012 till 9/2016; age, HE4, CA125, expert ultrasound examination of the pelvis, histotype, grade, FIGO stage. RESULTS: In total, 124 patients were enrolled. A cut-off of ≥113 pmol/l HE4 demonstrated 40.3% sensitivity and 83.9% specificity for detection of high-risk patients. Correlations of HE4 with age (p<0.001), depth of myometrial invasion (p=0.001), clinical stage of the disease according to ultrasound - T1a vs. T1b (63.6 pmol/l vs. 110.6 pmol/l, p<0.001) were found. However, no correlation of HE4 with lymph node invasion (p=0.07) and tumor grade (p=0.212) was identified. CONCLUSION: HE4 levels correspond to clinical and FIGO stage of the disease. The sensitivity and specificity does not reach the transvaginal ultrasound results in preoperative assessment of the extent of the disease. Combination of HE4 with ultrasound does not improve the stratification of patients into low-risk and high-risk groups. Preoperative assessment of HE4 is useful providing no imaging method is available.
Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias Endometriales/sangre , Proteínas/análisis , Anciano , Antígeno Ca-125/sangre , Neoplasias Endometriales/diagnóstico por imagen , Neoplasias Endometriales/patología , Neoplasias Endometriales/cirugía , Femenino , Humanos , Metástasis Linfática , Persona de Mediana Edad , Estadificación de Neoplasias , Periodo Preoperatorio , Ultrasonografía , Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAPRESUMEN
AIM: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125 and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. PATIENTS AND METHODS: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. RESULTS: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females with endometrial cancer 19.0 IU/l, versus healthy females, 15 IU/l. A significant correlation with histopathological disease stage was found for both biomarkers (Spearman correlation). Sensitivity and specificity, and the related cut-off for HE4 suggest that HE4 would be a more appropriate biomarker for differential diagnosis between benign and malignant states. CONCLUSION: Based on our pilot study, we found that parallel examination of HE4 and CA125 may support endometrial ultrasound finding verification prior to biopsy. This study is ongoing and we expect that results on a larger population may enable HE4 measurement to be implemented in routine practice.
Asunto(s)
Biomarcadores de Tumor/sangre , Antígeno Ca-125/sangre , Neoplasias Endometriales/diagnóstico , Proteínas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Neoplasias Endometriales/sangre , Neoplasias Endometriales/cirugía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Estadificación de Neoplasias , Proyectos Piloto , Cuidados Preoperatorios , Pronóstico , Curva ROC , Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAPRESUMEN
AIM: The first aim of the project was to evaluate the benefits of the determination of human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index for primary detection of ovarian cancer in a population of Czech women. The second aim was to study the advantages HE4, cancer antigen 125 (CA125) and ROMA index for distinguishing between benign and malignant tumors. Aware of the age distribution of ovarian cancer, we focused on postmenopausal patients. PATIENTS AND METHODS: Our group of patients consisted of 256 females, 21 with ovarian cancer and 235 with benign ovarian tumors. All diagnoses were histologically verified. We determined the serum levels of HE4 and CA125 and calculated the ROMA2 index for postmenopausal women. Serum levels of the analytes were measured using an Architect 1000i instrument. Serum samples were collected prior to surgery or any other form of treatment and the results of the two groups of patients were compared (malignant vs. benign). RESULTS: There was a significant difference in the serum levels for all parameters studied between the groups of patients with malignant and those with benign diagnoses (Wilcoxon test, p<0.0001). When all parameters were evaluated at 95% specificity, the HE4 cut-off was 112 pmol/l at a sensitivity of 71.42%, a positive predictive value (PPV) of 55.56%, a negative predictive value (NPV) of 97.14% and an area under the curve (AUC) of 0.9152. The CA125 cut-off was 81 IU/l at a sensitivity of 80.95%, a PPV of 58.62%, a NPV of 98.23% and an AUC of 0.9731. ROMA2 index had a cut-off 37.70% at a sensitivity of 85.71%, a PPV of 62.06%, a NPV of 98.65% and an AUC of 0.9803. The highest diagnostic efficiency was achieved by the ROMA2 index. CONCLUSION: Determination of HE4 along with CA125 and ROMA2 index calculation is a suitable method for the improvement of the primary detection of ovarian cancer. This approach also improves the differential diagnostic possibilities for distinguishing between malignant and benign tumors.
Asunto(s)
Enfermedades del Ovario/sangre , Neoplasias Ováricas/sangre , Posmenopausia/sangre , Proteínas/metabolismo , Factores de Edad , Algoritmos , Antígeno Ca-125/sangre , República Checa , Femenino , Humanos , Proteínas de la Membrana/sangre , Persona de Mediana Edad , Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAPRESUMEN
PROBLEM: The aim of this study was to investigate frequencies of eight antiphospholipid antibodies (aPLs) in serum, four genetic thrombophilic factors and their mutual relation in 206 patients with repeated pregnancy loss (RPL). METHOD OF STUDY: Enzyme-linked immunosorbent assay was used for detection of aPLs against ph-serine, ph-ethanolamine, ph-inositol, DL-glycerol, phosphatidic acid, anti-annexin V, cardiolipin, and beta2-GPI. FV 1691G>A (Leiden mutation), FII 20210G>A mutation, MTHFR 677C>T and MTHFR 1298A>C variant genotypes were determined using a melting curve analysis of the PCR amplification product detected by the fluorescence resonance energy transfer. Genotypic distribution and allelic frequencies were calculated. Correlation between aPLs and thrombophilic factors was tested by chi-square and Fisher exact test. RESULTS: Our results show significantly increased prevalence of aPLs against ph-inositol (17-19.6% dependent on number of spontaneous miscarriages) and against ph-serine (18-25%). aPLs in IgG prevail. In 96% of the studied group, at least one risk factor was found (either aPLs positivity or thrombophilic factor). Both aPLs and thrombophilic factors were present in 43%. In the group of women with three or more RPLs, strong positive correlation of aPLs positivity and thrombophilic risk factors was observed. CONCLUSION: Antiphospholipide antibodies and genetic thrombophilic factors are important risk factors in the pathogenesis of RPL. Both autoantibodies against various kinds of phospholipides and genetic thrombophilic factors must be studied together in diagnosis of RPL for appropriate treatment.
Asunto(s)
Aborto Habitual/genética , Aborto Habitual/inmunología , Anticuerpos Antifosfolípidos/genética , Anticuerpos Antifosfolípidos/inmunología , Trombofilia/genética , Trombofilia/inmunología , Aborto Habitual/epidemiología , Adulto , Anticuerpos Antifosfolípidos/biosíntesis , Anticuerpos Antifosfolípidos/sangre , Causalidad , Estudios Transversales , República Checa , Sondas de ADN , Ensayo de Inmunoadsorción Enzimática , Femenino , Frecuencia de los Genes/inmunología , Genotipo , Humanos , Persona de Mediana Edad , Mutación , Embarazo , Resultado del Embarazo , Factores de RiesgoRESUMEN
Seminal sperm-agglutinating antibodies along with IgG antibodies against laminin-1 and intraacrosomal sperm proteins were examined in seventy-one men from infertile couples. The direct mixed antiimmunoglobulin reaction test for IgG, IgA, and the commercial ELISA method for detecting IgG antibodies against laminin-1 in seminal plasma were used. Intraacrosomal proteins in the sperm heads were detected by immunofluorescence using monoclonal antibodies. Cellular elements other than spermatozoa, collectively referred to as "round cells" were also examined. In association with a group of oligoasthenospermatic men, positive levels (44%) of antibodies against laminin-1 of the IgG isotype in seminal plasma were found in conjunction with increased cellularity in semen. Interestingly, the elevated levels of anti-laminin-l IgG and sperm agglutinating positivity were not correlated. The use of antibodies against sperm antigens targeted to adhesive molecules such as laminin-1 contributes to diagnosing reproductive failure. Detection of intraacrosomal proteins very often correlates to the state of semen pathology and inflammation.
Asunto(s)
Acrosoma/inmunología , Autoanticuerpos/análisis , Autoanticuerpos/sangre , Infertilidad Masculina/inmunología , Laminina/inmunología , Semen/inmunología , Espermatozoides/inmunología , Acrosoma/química , Adulto , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunoglobulina A/análisis , Inmunoglobulina G/análisis , Masculino , Persona de Mediana Edad , Adulto JovenAsunto(s)
Episiotomía/métodos , Isquion , Adulto , Canal Anal/lesiones , Femenino , Humanos , Complicaciones del Trabajo de Parto/cirugía , Embarazo , Adulto JovenRESUMEN
La metodología de los estudios que evalúan el papel de la episiotomía mediolateral carece de la calidad necesaria y no puede extraerse actualmente de ellos conclusión alguna acerca del traumatismo perineal grave y la incontinencia anal. Se identificaron cuatro problemas: la definición y la ejecución práctica de la episiotomía mediolateral, y el diagnóstico y clasificación del traumatismo perineal. La definición y ejecución de la episiotomía mediolateral difieren ampliamente entre las distintas instituciones y los distintos individuos. El problema principal es la precisión de la dirección elegida. Se introdujeron tres términos: ángulo de incisión, de sutura y de cicatrización de episiotomía. Anteriormente, la episiotomía mediolateral se definía por un ángulo de incisión mínimo de 40°. Sin embargo,cuando se incide a 40°, el ángulo mediano luego de la reparación era de 20°, mientras que el ángulo de cicatrización era de 30° en los casos de desgarros de tercer grado frente a 38° en los controles. Al usar un ángulo de incisión de 60°, el ángulo mediano de sutura fue de 45° y el de cicatrización de 48°. Actualmente se propone que la episiotomía mediolateral se defina como una incisión en el perineo durante la última parte de la segunda etapa del trabajo de parto, que comienza en el perineo medial pero se dirige lateralmente en un ángulo de al menos 60° en dirección de la tuberosidad isquial. Se requieren más investigaciones para evaluar la seguridad de este ángulo de incisión.